Navigation Links
New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma

Raleigh, NC (PRWEB) July 23, 2014

Researchers in Turkey say a compound called EF24, which is chemically similar to the yellow pigment in the spice turmeric, and an immunosuppressor called RAD001 helped scientists destroy mesothelioma cells in the lab. To read the full story on Surviving Mesothelioma, click here now.

Scientists at Gazi University in Ankara, Turkey pretreated mesothelioma cells and healthy mesothelial cells with both compounds before exposing them to two platinum-based chemotherapy drugs with promising results.

According to lead study author Dr. H. Ilke Onen, “Our preliminary results suggest that pretreatment with EF24 or RAD001 may reduce the cytotoxic effect of cisplatin on nonmalignant mesothelial cells and increase cell death response of malignant pleural mesothelioma cells.”

Reporting in Human & Experimental Toxicology, the team also found that healthy cells pretreated with the two compounds tended to experience less DNA damage when they were exposed to the chemotherapy drugs.

“Many of the serious side effects for mesothelioma patients on chemotherapy come from damage to healthy cells,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “This study is encouraging because it suggests there may be a way to protect those cells while still delivering a lethal dose of chemotherapy to mesothelioma tumors.”

To read the details of this exciting new study, including the next steps for research on EF24 and RAD001, see Mesothelioma Cells Respond Better to Chemotherapy Drug When Pretreated with Two Compounds now available on the Surviving Mesothelioma website.

Onen, H et al, “EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelioma (MET-5A) cells”, July 15, 2014, Human & Experimental Toxicology, Epub ahead of print.

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. University of Utah researcher Robert Marc receives Paul Kayser International Award
2. New research finds pathogenic connection between autoimmune disorders and cancer
3. Research brings us nearer to understanding how neuro cells turn cancerous
4. Global Molecular Diagnostics Market Expected to Reach USD 8.7 Billion through 2019: Transparency Market Research
5. SkillSurvey to Present Research on Contingent Workers at National Association for Health Care Recruitment IMAGE 2014 Conference
6. Growth of Disposable Medical Supplies Market to 2019 Report Available at
7. Hypatia Research Group Publishes “Enterprise Governance, Risk & Compliance: Best Practices, Maturity Models and 2014 ProductMatrix Vendor Evaluations”
8. Communication about female condom vital to young adults, UT Arlington researchers say
9. Chocolate Production in Canada Industry Market Research Report Now Available from IBISWorld
10. New research from Africa on pharmacomicrobiomics
11. Indoor Sports Facilities Management in the US Industry Market Research Report from IBISWorld Has Been Updated
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center ... and is the only hospital in the region providing what is known as ... transcatheter pacing patients were revealed recently at a medical conference and published in ...
(Date:12/1/2015)... MD (PRWEB) , ... December 01, 2015 , ... ... salmon identification tests to continue the expansion of the company’s growing product line ... – for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... Health Center of Excellence (BHCOE) today announced that the organization has awarded Education ... San Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or ... anticipated results, once a deal is signed. This quick-read guidance suggests that ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: